Literature DB >> 16632217

The conundrum of follow-up: should it be abandoned?

Omgo E Nieweg1, Bin B R Kroon.   

Abstract

This article critically evaluates the practice of follow-up for patients who have undergone treatment for a primary melanoma without evidence of metastases. One conclusion from this analysis is that the benefits of routine imaging and blood testing are insufficient to warrant a place in routine follow-up. Few patients who have metastases are identified in this fashion and even fewer survive because they underwent these tests. Far more often, false-positive results occur, which invariably cause unnecessary concern, lead to additional unnecessary testing, and may even result in needless surgery. Based on the evidence available, the relevance of follow-up per se must even be challenged. No convincing evidence exists that regional control, survival, and quality of life improve through surveillance. Other reasons for surveillance may be present, but these are less imperative. The present findings challenge current practice.

Entities:  

Mesh:

Year:  2006        PMID: 16632217     DOI: 10.1016/j.soc.2005.12.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  9 in total

1.  High-risk cutaneous melanoma follow-up: time for more intensive surveillance?

Authors:  Michael Davidson; Paul Lorigan; James Larkin
Journal:  Melanoma Manag       Date:  2014-09-05

2.  It is never too late: ultra-late recurrence of melanoma with distant metastases.

Authors:  Dina Mansour; Deepak Kejariwal
Journal:  BMJ Case Rep       Date:  2012-03-08

Review 3.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

4.  Is GP-led follow-up feasible?

Authors:  A B Francken; J W Hoekstra-Weebers; H J Hoekstra
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 5.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

6.  TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.

Authors:  Ylva Naeser; Hildur Helgadottir; Yvonne Brandberg; Johan Hansson; Roger Olofsson Bagge; Nils O Elander; Christian Ingvar; Karolin Isaksson; Petra Flygare; Cecilia Nilsson; Frida Jakobsson; Olga Del Val Munoz; Antonis Valachis; Malin Jansson; Charlotte Sparring; Lars Ohlsson; Ulf Dyrke; Dimitrios Papantoniou; Anders Sundin; Gustav J Ullenhag
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

7.  Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse.

Authors:  Yanina J L Jansen; Inneke Willekens; Teofila Seremet; Gil Awada; Julia Katharina Schwarze; Johan De Mey; Carola Brussaard; Bart Neyns
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

8.  Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Authors:  April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 9.  Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis.

Authors:  Rachel K Voss; Tessa N Woods; Kate D Cromwell; Kelly C Nelson; Janice N Cormier
Journal:  Patient Relat Outcome Meas       Date:  2015-11-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.